The deal will allow Hologic to add laparoscopic vessel sealing, dividing and dissecting devices to its portfolio, in addition to expanding the use of Bolder’s devices to OB/GYN specialists
Bolder Surgical offers advanced energy vessel sealing and dissection tools for surgical gynecologists in both laparoscopic and open procedures. (Credit: Sasin Tipchai from Pixabay)
Medical technology firm Hologic has agreed to acquire US-based energy vessel sealing surgical devices provider Bolder Surgical for around $160m.
Bolder Surgical is engaged in the development and manufacturing of advanced energy vessel sealing and dissection tools for surgical gynaecologists in both laparoscopic and open procedures.
The company offers CoolSeal devices, which feature slender and dual-action jaws that enable dissection, vessel sealing and dividing with one device.
It also offers JustRight 3mm vessel sealer and the JustRight 5mm stapler for use in small surgical spaces, including paediatric cases.
Based in Louisville, Colorado, the company supplies its products to customers in all 50 states across the US and internationally.
According to Hologic, the potential to use a combination device enhances surgical efficiency by reducing the requirement for instrument exchanges.
Bolder Surgical president and CEO Robert Kline said: “Becoming part of Hologic and its highly respected and well-known Surgical business is an exciting and pivotal junction for Bolder.
“Together, we will accelerate realising Bolder’s vision to increase the efficiency of both surgeons and hospitals. Joining Hologic, with its similar mission, culture, and world-class portfolio of products, is an ideal fit for Bolder.”
The deal will allow Hologic to add laparoscopic vessel sealing, dividing and dissecting devices to its portfolio, in addition to expanding the use of Bolder’s devices to OB/GYN specialists.
The acquisition also compliments Hologic’s surgical product portfolio, which consists of a NovaSure endometrial ablation system to treat abnormal uterine bleeding and MyoSure tissue removal devices to treat intrauterine fibroids and polyps.
Hologic’s other surgical devices include Acessa laparoscopic radiofrequency ablation system to treat fibroids and the Fluent fluid management system to streamline hysteroscopic procedures.
Hologic chairman, president and CEO Steve MacMillan said: “This acquisition is another good example of our capital deployment strategy, as we use our strong cash flow to add products that leverage our existing channel strength and accelerate our growth.”
Subject to antitrust clearance and other customary closing conditions, the deal is expected to be completed by the end of this year.
Earlier this year, Hologic acquired European company Diagenode, which develops and produces molecular diagnostic assays and epigenetics products.